Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IVF study probes nasal Spray's hidden role in pregnancy support

NCT ID NCT07620067

Knowledge-focused Sponsor: Heli Alexandroni Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a nasal spray (GnRH agonist) helps support the early stages of pregnancy after IVF. Researchers will measure hormones and other substances in the blood and fluid around the eggs to understand the spray's effects. The study involves 150 women aged 18-45 undergoing their first to third IVF cycle with a fresh embryo transfer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

women undergoing IVF treatment with OPU and ET

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women included in the study will be 18-45 years old * undergoing IVF treatments due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility. * All women will be at their first to the third cycle of treatment * women will undergo a fresh ET. Exclusion Criteria: * repeated implantation failure (more than 3 cycles of good quality ET without implantation) * moderate-severe endometriosis * hydrosalpinx * fibroid uterus * BMI more than 35 or less than 19 * women with hypogonadotropic hypogonadism * PGT of embryos * use of surgical techniques for sperm retrieval * preference of the long GnRH-agonist protocol * women with rhinitis or nasal congestion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Administration of hormonal luteal support are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Administration of hormonal luteal support Fresh embryo transfer GNRH antagonist ivf protocol

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, 9103102, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.